QQQ   426.61 (-1.04%)
AAPL   168.20 (-0.70%)
MSFT   411.91 (-0.64%)
META   495.05 (-0.94%)
GOOGL   155.69 (+0.84%)
AMZN   181.23 (-1.14%)
TSLA   156.65 (-0.29%)
NVDA   845.45 (-3.28%)
AMD   155.00 (-5.18%)
NIO   3.94 (+3.41%)
BABA   68.96 (-0.93%)
T   16.14 (+0.31%)
F   12.04 (-0.41%)
MU   116.64 (-4.21%)
GE   155.47 (-0.82%)
CGC   6.41 (-4.33%)
DIS   113.22 (-0.58%)
AMC   2.98 (+9.56%)
PFE   25.43 (-1.01%)
PYPL   63.29 (-0.22%)
XOM   118.51 (-0.15%)
QQQ   426.61 (-1.04%)
AAPL   168.20 (-0.70%)
MSFT   411.91 (-0.64%)
META   495.05 (-0.94%)
GOOGL   155.69 (+0.84%)
AMZN   181.23 (-1.14%)
TSLA   156.65 (-0.29%)
NVDA   845.45 (-3.28%)
AMD   155.00 (-5.18%)
NIO   3.94 (+3.41%)
BABA   68.96 (-0.93%)
T   16.14 (+0.31%)
F   12.04 (-0.41%)
MU   116.64 (-4.21%)
GE   155.47 (-0.82%)
CGC   6.41 (-4.33%)
DIS   113.22 (-0.58%)
AMC   2.98 (+9.56%)
PFE   25.43 (-1.01%)
PYPL   63.29 (-0.22%)
XOM   118.51 (-0.15%)
QQQ   426.61 (-1.04%)
AAPL   168.20 (-0.70%)
MSFT   411.91 (-0.64%)
META   495.05 (-0.94%)
GOOGL   155.69 (+0.84%)
AMZN   181.23 (-1.14%)
TSLA   156.65 (-0.29%)
NVDA   845.45 (-3.28%)
AMD   155.00 (-5.18%)
NIO   3.94 (+3.41%)
BABA   68.96 (-0.93%)
T   16.14 (+0.31%)
F   12.04 (-0.41%)
MU   116.64 (-4.21%)
GE   155.47 (-0.82%)
CGC   6.41 (-4.33%)
DIS   113.22 (-0.58%)
AMC   2.98 (+9.56%)
PFE   25.43 (-1.01%)
PYPL   63.29 (-0.22%)
XOM   118.51 (-0.15%)
QQQ   426.61 (-1.04%)
AAPL   168.20 (-0.70%)
MSFT   411.91 (-0.64%)
META   495.05 (-0.94%)
GOOGL   155.69 (+0.84%)
AMZN   181.23 (-1.14%)
TSLA   156.65 (-0.29%)
NVDA   845.45 (-3.28%)
AMD   155.00 (-5.18%)
NIO   3.94 (+3.41%)
BABA   68.96 (-0.93%)
T   16.14 (+0.31%)
F   12.04 (-0.41%)
MU   116.64 (-4.21%)
GE   155.47 (-0.82%)
CGC   6.41 (-4.33%)
DIS   113.22 (-0.58%)
AMC   2.98 (+9.56%)
PFE   25.43 (-1.01%)
PYPL   63.29 (-0.22%)
XOM   118.51 (-0.15%)

Ligand Pharmaceuticals (LGND) SEC Filings & 10K Form

$79.45
-0.47 (-0.59%)
(As of 03:21 PM ET)

Recent Ligand Pharmaceuticals SEC Filings

DateFilerForm TypeView
03/27/2024
4:47 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/07/2024
12:27 PM
Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2024
4:28 PM
Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2024
5:12 PM
Ligand Pharmaceuticals (Subject)
Sabba Stephen L (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/29/2024
5:49 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
5:50 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
5:50 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
5:50 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/29/2024
3:49 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144/A
02/29/2024
3:16 PM
Ligand Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/28/2024
5:05 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/28/2024
4:43 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/27/2024
6:24 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/16/2024
7:10 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
7:10 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
7:10 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
7:10 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2024
5:26 AM
Ligand Pharmaceuticals (Subject)
MACQUARIE GROUP LTD (Filed by)
Form SC 13G
02/13/2024
2:39 PM
JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
02/12/2024
6:42 PM
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G
01/22/2024
1:03 PM
BlackRock Inc. (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
01/04/2024
3:07 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2024
3:07 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/06/2023
2:27 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/06/2023
2:27 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2023
7:25 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/18/2023
8:03 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/03/2023
3:36 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2023
7:38 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/26/2023
3:41 PM
Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2023
5:12 PM
Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/25/2023
3:44 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2023
4:26 PM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2023
3:20 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2023
5:42 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2023
5:42 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
8:28 AM
Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:52 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:53 PM
Haas Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:54 PM
Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:54 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
IRS Loophole Gives Americans An Escape From Inflation (Ad)

In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.

Request your info kit on gold now
06/13/2023
5:55 PM
LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:55 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2023
4:18 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2023
2:43 PM
Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/10/2023
6:07 PM
Ligand Pharmaceuticals (Subject)
Sabba Stephen L (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/10/2023
6:15 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2023
3:06 PM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:LGND) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners